ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results

We recently published 10 Stock Winners Shocking Wall Street. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers last week.

ImmunityBio skyrocketed by 137 percent week-on-week to hit a new record high after rallying for 11 consecutive days, thanks to a flurry of catalysts, including a whopping surge in its sales, its expansion to a new international market, and the promising results from the clinical trial of its treatment candidate for a rare blood cancer.

In a recent clinical study of its CD19 CAR-NK treatment, in combination with rituximab, ImmunityBio Inc. (NASDAQ:IBRX) said that the therapy successfully controlled disease in four patients enrolled in the program, two of whom demonstrated complete remission at 7 and 15 months despite not receiving additional treatments after the initial eight doses.

After only two cycles, ImmunityBio Inc. (NASDAQ:IBRX) said the tumors disappeared completely. It said that the durability of complete response after ending the treatment underscores the potential for long-term immune-mediated disease control without continuous therapy.

Meanwhile, ImmunityBio Inc. (NASDAQ:IBRX) recently announced a 700 percent jump in preliminary revenues from its treatment, Anktiva, having raked in $113 million for the full-year 2025 amid strong demand.

ImmunityBio Inc. (NASDAQ:IBRX) is set to expand Anktiva in Saudi Arabia after securing the approval of the Food and Drug Administration to sell and market the drug in the country.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.